Advances in medical therapy of inflammatory bowel disease

Current Opinion in Pharmacology

Volumn 5, Issue 6 SPEC. ISS., 2005, Pages 566-572

  Panaccione, Remo ^a   Ferraz, Jose G ^a   Beck, Paul ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA4 INTEGRIN; AZATHIOPRINE; C REACTIVE PROTEIN; CELL SURFACE RECEPTOR; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; FONTOLIZUMAB; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 18 ANTIBODY; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MLN 02; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; ONERCEPT; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TACROLIMUS; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

BETA CHAIN; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENTERITIS; HUMAN; INFECTION; LEUKOENCEPHALOPATHY; LIVER TOXICITY; LYMPHOCYTE TRANSFER; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

EID: 27744503422     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.08.003     Document Type: Review

References (63)

1. W.J. Sandborn B.G. Feagan Mild to moderate Crohn's disease: Defining the basis for a new treatment algorithm Aliment Pharmacol Ther 18 2003 263-277
2. P. Rutgeerts G. Van Assche S. Vermeire G. D'Haens F. Baert M. Noman I. Aerden G. De Hertogh K. Geboes M. Hiele D'Hoore et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial Gastroenterology 128 2005 856-861
3. J.M. Van den Brande H. Braat G.R. van den Brink H.H. Versteeg C.A. Bauer I. Hoedemaeker Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 2003 1774-1785
4. S.R. Targan S.B. Hanauer S.J. van Deventer L. Mayer D.H. Present T. Braakman K.L. DeWoody T.F. Schaible P.J. Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1997 1029-1035
5. D.H. Present P. Rutgeerts S. Targan S.B. Hanauer L. Mayer R.A. van Hogezand D.K. Podolsky B.E. Sands T. Braakman K.L. DeWoody et al. Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398-1405
6. G. D'haens S. Van Deventer R. Van Hogezand D. Chalmers C. Kothe F. Baert T. Braakman T. Schaible K. Geboes P. Rutgeerts Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial Gastroenterology 116 1999 1029-1034
7. S.B. Hanauer B.G. Feagan G.R. Lichtenstein L.F. Mayer S. Schreiber J.F. Colombel D. Rachmilewitz D.C. Wolf A. Olson W. Bao P. Rutgeerts ACCENT I Study Group: Maintenance infliximab foT Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541-1549
8. B.E. Sands F.H. Anderson C.N. Bernstein W.Y. Chey B.G. Feagan R.N. Fedorak M.A. Kamm J.R. Korzenik B.A. Lashner J.E. Onken et al. Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876-885
9. P. Rutgeerts B.G. Feagan G.R. Lichtenstein L.F. Mayer S. Schreiber J.F. Colombel D. Rachmilewitz D.C. Wolf A. Olson W. Bao et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology 126 2004 402-413
10. G.R. Lichtenstein S. Yan M. Bala M. Blank B.E. Sands Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease Gastroenterology 128 2005 862-869
11. G.R. Lichtenstein S. Yan M. Bala S. Hanauer Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries Am J Gastroenterol 99 2004 91-96
12. B.G. Feagan S. Yan M. Bala W. Bao G.R. Lichtenstein The effects of infliximab maintenance therapy on health-related quality of life Am J Gastroenterol 98 2003 2232-2238
13. J.F. Colombel E.V. Loftus Jr. W.J. Tremaine L.J. Egan W.S. Harmsen C.D. Schleck A.R. Zinsmeister W.J. Sandborn The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients Gastroenterology 126 2004 19-31
14. J.A. Katz C. Antoni G.F. Keenan D.E. Smith S.J. Jacobs G.R. Lichtenstein Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis Am J Gastroenterol 99 2004 2385-2392
15. J.F. Colombel E.V. Loftus Jr. W.J. Tremaine J.H. Pemberton B.G. Wolff T. Young-Fadok W.S. Harmsen C.D. Schleck W.J. Sandborn Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy Am J Gastroenterol 99 2004 878-883
16. L. Marchal G. D'Haens G. Van Assche S. Vermeire M. Noman M. Ferrante M. Hiele M. Bueno De Mesquita A. D'Hoore F. Penninckx et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study Aliment Pharmacol Ther 19 2004 749-754
17. F. Baert M. Noman S. Vermeire G. Van Assche G. D' Haens A. Carbonez P. Rutgeerts Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601-608
18. S.B. Hanauer C.L. Wagner M. Bala L. Mayer S. Travers R.H. Diamond A. Olson W. Bao P. Rutgeerts Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clin Gastroenterol Hepatol 2 2004 542-553
19. R.J. Farrell M. Alsahli Y.T. Jeen K.R. Falchuk M.A. Peppercorn P. Michetti Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial Gastroenterology 124 2003 917-924
20. S. Schreiber P. Rutgeerts R.N. Fedorak M. Khaliq Kareemi M.A. Kamm M. Boivin C.N. Bernstein M. Staun O.O. Thomsen A. Innes A randomized, placebo-controlled trial of Certolizumab Pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 2005 807-818
21. W.J. Sandborn S. Hanauer E.V. Loftus Jr. W.J. Tremaine S. Kane R. Cohen K. Hanson T. Johnson D. Schmitt R. Jeche An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease Am J Gastroenterol 99 2004 1984-1989
22. A. Youdim E.A. Vasiliauskas S.R. Targan K.A. Papadakis A. Ippoliti M.C. Dubinsky J. Lechago J. Paavola J. Loane S.K. Lee et al. A pilot study of adalimumab in infliximab-allergic patients Inflamm Bowel Dis 10 2004 333-338
23. K.A. Papadakis O.A. Shaye E.A. Vasiliauskas A. Ippoliti M.C. Dubinsky J. Birt J. Paavola S.K. Lee J. Price S.R. Targan M.T. Abreu Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab Am J Gastroenterol 100 2005 75-79
24. S. Hanauer M. Lukas D. MacIntosh P. Rutgeerts W. Sandborn P. Pollock A randomized, double blind, placebo-controlled trial of the human anti-TNFα monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Chohn's disease Gastroenterology 127 2004 331-333
25. W. Sandborn S. Hanauer M. Lukas D.C. Wolf K.L. Isaacs D.G. MacIntosh R. Panaccione P. Rutgeerts P.F. Pollock Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6 month open-label period with fully human anti-TNFα monoclonal antibody adalimumab (Humira®) Gastroenterology 128 2005 A723
26. F.H. Gordon C.W. Lai M.I. Hamilton M.C. Allison E.D. Srivastava M.G. Fouweather S. Donoghue C. Greenlees J. Subhani P.L. Amlot et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease Gastroenterology 121 2001 268-274
27. S. Ghosh E. Goldin F.H. Gordon H.A. Malchow J. Rask-Madsen P. Rutgeerts P. Vyhnalek Z. Zadorova T. Palmer S. Donoghue Natalizumab Pan-European Study Group: Natalizumab for active Crohn's disease N Engl J Med 348 2003 24-32
28. A. Langer-Gould S.W. Atlas A.J. Green A.W. Bollen D. Pelletier Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 353 2005 375-381
29. B.K. Kleinschmidt-DeMasters K.L. Tyler Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 2005 369-374
30. G. Van Assche M. Van Ranst R. Sciot B. Dubois S. Vermeire M. Noman J. Verbeeck K. Geboes W. Robberecht P. Rutgeerts Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 2005 362-368
31. P.J. Mannon I.J. Fuss L. Mayer C.O. Elson W.J. Sandborn D. Present B. Dolin N. Goodman C. Groden R.L. Hornung et al. Anti-interleukin-12 antibody for active Crohn's disease N Engl J Med 351 2004 2069-2079
32. P. Rutgeerts R. Enns J.F. Colombel B. Feagan S. Hanauer I. Lawrence R. Panaccione M. Sanders S. Schreiber S. Targan et al. 6-month steroid sparing results of natalizumab in a controlled study of patients with Crohn's disease Gut 53 2004 A48
33. W.J. Sandborn J-F. Colombel R. Enns R. Panaccione I. Lawrence S. Schreiber S. Targan B. Feagan M. Sanders P. Rutgeerts Efficacy of natalizumab in maintaining clinical response and remission: Results from ENACT-2 Gastroenterology 126 2004 A730
34. B. Feagan G. Greenberg G. Wild J.W.D. McDonald R. Fedorak P. Pare K. Kishimoto J.C. Gutierrez-Ramos J. Krop Efficacy and safety of a humanized α4β7 antibody in active Crohn's disease (CD) Gastroenterology 124 2003 A178
35. J.R. Korzenik B.K. Dieckgraefe J.F. Valentine D.F. Hausman M.J. Gilbert Sargramostim in Crohn's Disease Study Group: Sargramostim for active Crohn's disease N Engl J Med 352 2005 2193-2201
36. D.N. Prajapati J.F. Knox J. Emmons K. Saeian M.E. Csuka D.G. Binion Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy J Clin Gastroenterol 37 2003 125-128
37. D.C. Baumgart B. Wiedenmann A.U. Dignass Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease Aliment Pharmacol Ther 17 2003 1273-1281
38. W.J. Sandborn D.H. Present K.L. Isaacs D.C. Wolf E. Greenberg S.B. Hanauer B.G. Feagan L. Mayer T. Johnson J. Galanko et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: A randomized, placebo-controlled trial Gastroenterology 125 2003 380-388
39. W. Miehsler W. Reinisch G. Moser A. Gangl H. Vogelsang Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 96 2001 782-787
40. M.F. Neurath R. Wanitschke M. Peters F. Krummenauer K.H. Meyer zum Buschenfelde J.F. Schlaak Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease Gut 44 1999 625-628
41. A.C. Ford R.J. Towler P. Moayyedi D.M. Chalmers A.T. Axon Mycophenolate mofetil in refractory inflammatory bowel disease Aliment Pharmacol Ther 17 2003 1365-1369
42. M.C. Dubinsky P.V. Hassard E.G. Seidman L.Y. Kam M.T. Abreu S.R. Targan E.A. Vasiliauskas An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy Inflamm Bowel Dis 7 2001 181-189
43. M.C. Dubinsky E.J. Feldman M.T. Abreu S.R. Targan E.A. Vasiliauskas Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine Am J Gastroenterol 98 2003 1058-1063
44. M.C. Dubinsky E.A. Vasiliauskas H. Singh M.T. Abreu K.A. Papadakis T. Tran P. Martin J.M. Vierling S.A. Geller S.R. Targan et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients Gastroenterology 125 2003 298-303
45. S. Shastri M.C. Dubinsky F. Fred Poordad E.A. Vasiliauskas S.A. Geller Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy Arch Pathol Lab Med 128 2004 49-53
46. S. Lichtiger D.H. Present A. Kornbluth I. Gelernt J. Bauer G. Galler F. Michelassi S. Hanauer Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841-1845
47. J. Arts G. D'Haens M. Zeegers G. Van Assche M. Hiele A. D'Hoore F. Penninckx S. Vermeire P. Rutgeerts Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis Inflamm Bowel Dis 10 2004 73-78
48. G. Van Assche G. D'Haens M. Noman S. Vermeire M. Hiele K. Asnong J. Arts A. D'Hoore F. Penninckx P. Rutgeerts Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis Gastroenterology 125 2003 1025-1031
49. W.Y. Chey A. Hussain C. Ryan G.D. Potter A. Shah Infliximab for refractory ulcerative colitis Am J Gastroenterol 96 2001 2373-2381
50. C. Su B.A. Salzberg J.D. Lewis J.J. Deren A. Kornbluth D.A. Katzka R.B. Stein D.R. Adler G.R. Lichtenstein Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis Am J Gastroenterol 97 2002 2577-2584
51. G.C. Actis M. Bruno M. Pinna-Pintor F.P. Rossini M. Rizzetto Infliximab for treatment of steroid-refractory ulcerative colitis Dig Liver Dis 34 2002 631-634
52. C.S. Probert S.D. Hearing S. Schreiber T. Kuhbacher S. Ghosh I.D. Arnott A. Forbes Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial Gut 52 2003 998-1002
53. W. Sandborn D. Rachmilewitz S. Hanauer G. Lichtenstein W. deVilliers A. Olson J. Johanns S. Travers J.F. Colombel Infliximab induction and maintenance therapy for ulcerative colitis: The ACT2 trial Gastroenterology 128 2005 A688
54. P. Rutgeerts B. Feagan A. Olson J. Johanns S. Travers D. Present B. Sands W. Sandborn A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act1 trial Gastroenterology 128 2005 A689
55. G. Jarnerot E. Hertervig I. Friis-Liby L. Blomquist P. Karlen C. Granno M. Vilien M. Strom A. Danielsson H. Verbaan et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study Gastroenterology 128 2005 1805-1811
56. G.J. Mantzaris M. Sfakianakis E. Archavlis K. Petraki A. Christidou A. Karagiannidis G. Triadaphyllou A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis Am J Gastroenterol 99 2004 1122-1128
57. S. Campbell S. Ghosh Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: The Edinburgh experience of outcome Dig Liver Dis 35 2003 546-551
58. P.L. Beck D.K. Podolsky Growth factors in inflammatory bowel disease Inflamm Bowel Dis 5 1999 44-60
59. A. Chowdhury R. Fukuda S. Fukumoto Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients J Gastroenterol 31 1996 353-360
60. A. Sinha J.M.D. Nightingale K.P. West J. Berlanga-Acosta R.J. Playford Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis N Engl J Med 349 2003 350-357
61. B.G. Feagan G.R. Greenberg G. Wild R.N. Fedorak P. Pare J.W.D. McDonald R. Dube A. Cohen A.H. Steinhart S. Landau et al. Treatment of ulcerative colitis with a humanized α4β7 integrin N Engl J Med 352 2005 2499-2507
62. S. Plevy B. Salzberg G. van Assche M. Regueiro W. Sandborn S. Hanauer S. Targan L. Mayer U. Mahadevan J. Lowder A humanized anti-CD3 monoclonal antibody, visilizumab, for the treatment of severe steroid refractory ulcerative colitits: Results of a Phase I study Gastroenterology 126 2004 A579
63. S. Targan B. Salzberg L. Mayer D. Hommes S. Hanauer U. Mahadevan W. Reinisch S. Plevy A. Dignass G. van Assche et al. A phase I-II: multi-dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with iv steroids (IVSR-UC) Gastroenterology 128 2005 A493